Gateway 2012: Stäubli
Your online Gateway to Stäubli in 2012
About Stäubli
With presence in 25 countries, Stäubli is recognized worldwide for providing unrivaled quality and innovative technology. Since 1982, Stäubli has led the development of innovative solutions to improve productivity, safety, and product quality in robotics. Stäubli offers a comprehensive product range, including 4-axis SCARA and 6-axis robots for payloads of up to 250 kg. All robotic systems operate on the CS8 controller platform, which is perfectly adpated to robotics. Today, Stäubli Robotics is the leading-edge player in robotics around the world with its engineering as effective and dependable as its sales and services. Stäubli Robotics provides high performance, innovative and flexible solutions to satisfy the requirements of each industry. Designed to work in the most hostile environments as well as cleanrooms, Stäubli robots demonstrate their efficacy under all conditions.
New Products at Stäubli
The clean, precise and highly accurate range of Stericlean six axis robots provide the ideal solution to the unique set of requirements that automation in pharmaceutical, medical, and life sciences industries demand. Stericlean is the first fully VHP (Vapor Hydrogen Peroxide) resistant robot, providing fully automated operations in an isolator or cleanroom environment.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
